Profile data is unavailable for this security.
About the company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.
- Revenue in USD (TTM)0.00
- Net income in USD-163.66m
- Incorporated2012
- Employees74.00
- LocationAtea Pharmaceuticals Inc225 Franklin Street, Suite 2100BOSTON 02110United StatesUSA
- Phone+1 (857) 204-8109
- Fax+1 (302) 655-5049
- Websitehttps://ateapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | 236.65m | -313.72m | 296.63m | 534.00 | -- | -- | -- | 1.25 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 297.39m | 203.00 | -- | 0.5467 | -- | 1.67 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 298.14m | 59.00 | -- | 2.51 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 298.69m | 1.60k | -- | 0.4499 | -- | 0.252 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 299.45m | 50.00 | -- | 2.24 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| XOMA Corp | 5.81m | -45.09m | 300.16m | 13.00 | -- | 3.65 | -- | 51.65 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Q32 Bio Inc | 354.00k | -83.09m | 304.52m | 39.00 | -- | 6.24 | -- | 860.24 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -163.66m | 309.10m | 74.00 | -- | 0.6128 | -- | -- | -1.96 | -1.96 | 0.00 | 5.99 | 0.00 | -- | -- | 0.00 | -27.48 | -5.90 | -28.78 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 311.39m | 5.50k | 5.30 | 7.91 | 4.47 | 0.752 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 315.10m | 402.00 | -- | 2.59 | -- | 27.69 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Solid Biosciences Inc | 0.00 | -90.25m | 317.01m | 88.00 | -- | 1.48 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 321.53m | 67.00 | -- | 1.67 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 33.90m | -92.95m | 322.57m | 116.00 | -- | -- | -- | 9.52 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Fractyl Health Inc | 148.00k | -83.16m | 322.83m | 102.00 | -- | 3.84 | -- | 2,181.25 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -215.79m | 323.66m | 331.00 | -- | 0.8642 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Data as of May 31 2024. Currency figures normalised to Atea Pharmaceuticals Inc's reporting currency: US Dollar USD
45.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.57m | 7.81% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 6.15m | 7.30% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.78m | 6.87% |
| BML Capital Management LLCas of 31 Mar 2024 | 5.54m | 6.58% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.65m | 5.53% |
| Tang Capital Management LLCas of 31 Mar 2024 | 4.08m | 4.84% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.88m | 2.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.68m | 1.99% |
| Tyrus Capital S.A.M.as of 30 Sep 2023 | 1.26m | 1.50% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.12m | 1.34% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
